Seralutinib Partnership Gossamer Bio is a clinical-stage company focused on seralutinib for PAH and PH-ILD, presenting a potential co-development or licensing opportunity for larger biopharmas seeking entry into niche pulmonary vascular indications. Partnerships could include upfronts, milestones, and regional commercialization deals as programs advance.

Clinical Ops Outsourcing With a mid-size team and ongoing PAH/PH-ILD programs, there is a clear opportunity to engage CROs and CDMOs for trial design, patient recruitment, endpoints development, and clinical-material manufacturing to accelerate timelines and optimize trial performance.

Regulatory Compliance Recent investor-focused litigation activity signals a need for strengthened regulatory strategy, compliance, pharmacovigilance, and investor communications support to stabilize disclosures and governance processes.

Data Security Gossamer's tech footprint and emphasis on cybersecurity frameworks indicate potential demand for data integration, cloud optimization, analytics for R&D and pharmacovigilance, plus security audits and regulatory-compliant data sharing with partners.

Investor Relations As a NASDAQ-listed company with tens of millions in revenue and ongoing class-action coverage, there is opportunity to offer investor relations platforms, crisis communications, and analyst relations services to bolster investor confidence and market reach.